Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference By: Immunome, Inc. via Business Wire January 03, 2024 at 08:00 AM EST Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 8 at 7:30 a.m. PT. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days. About Immunome, Inc. Immunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality appropriate to its biology, including radioligand therapies, ADCs, and immunotherapies. We believe that pursuing underexplored targets with appropriate drug modalities leads to transformative therapies. Our proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of novel antibodies and targets. For more information, visit www.immunome.com or follow us on Twitter and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20240103115774/en/Contacts Investor Contact Max Rosett Interim Chief Financial Officer investors@immunome.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference By: Immunome, Inc. via Business Wire January 03, 2024 at 08:00 AM EST Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 8 at 7:30 a.m. PT. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days. About Immunome, Inc. Immunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality appropriate to its biology, including radioligand therapies, ADCs, and immunotherapies. We believe that pursuing underexplored targets with appropriate drug modalities leads to transformative therapies. Our proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of novel antibodies and targets. For more information, visit www.immunome.com or follow us on Twitter and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20240103115774/en/Contacts Investor Contact Max Rosett Interim Chief Financial Officer investors@immunome.com
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 8 at 7:30 a.m. PT. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days. About Immunome, Inc. Immunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality appropriate to its biology, including radioligand therapies, ADCs, and immunotherapies. We believe that pursuing underexplored targets with appropriate drug modalities leads to transformative therapies. Our proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of novel antibodies and targets. For more information, visit www.immunome.com or follow us on Twitter and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20240103115774/en/